Drug Guide
Secobarbital Sodium
Classification
Therapeutic: Sedative-Hypnotic
Pharmacological: Barbiturate
FDA Approved Indications
- Short-term treatment of insomnia
- Sedation prior to medical procedures
Mechanism of Action
Secobarbital binds to GABA-A receptors, enhancing the inhibitory effects of gamma-aminobutyric acid (GABA), leading to sedative, hypnotic, and anticonvulsant effects.
Dosage and Administration
Adult: Typically 100-200 mg at bedtime; dosage adjusted based on response and tolerability.
Pediatric: Not generally recommended due to safety concerns.
Geriatric: Start at lower end of dosing range, monitor closely for adverse effects.
Renal Impairment: Use with caution; dosage adjustments may be necessary.
Hepatic Impairment: Use with caution; monitor for increased sedation.
Pharmacokinetics
Absorption: Rapid absorption from the gastrointestinal tract.
Distribution: Widely distributed, crosses the blood-brain barrier.
Metabolism: Metabolized in the liver, primarily via hydroxylation and conjugation.
Excretion: Excreted mainly in the urine as metabolites.
Half Life: Approximately 15-48 hours, varies with dose and frequency.
Contraindications
- History of porphyria, respiratory depression, or hypersensitivity to barbiturates.
Precautions
- Use with caution in patients with a history of substance abuse, elderly, pregnancy, and in those with hepatic or renal impairment. Avoid abrupt discontinuation to prevent withdrawal symptoms.
- Pregnancy category D: risk to fetus; use only if benefits outweigh risks.
Adverse Reactions - Common
- Drowsiness (Common)
- Dizziness (Common)
- Memory impairment (Common)
Adverse Reactions - Serious
- Respiratory depression (Less common but serious)
- Dependence and addiction (Serious)
- Potential for overdose leading to coma or death (Serious)
Drug-Drug Interactions
- Other CNS depressants (e.g., alcohol, benzodiazepines, opioids) increase sedation and respiratory depression risk.
- CYP450 enzyme inducers (e.g., rifampin) may decrease effectiveness.
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for signs of CNS depression, respiratory depression, and dependence.
Diagnoses:
- Risk for sedation, Fall risk, Risk for dependence.
Implementation: Administer at bedtime; avoid alcohol and other CNS depressants; monitor patient response.
Evaluation: Assess sleep quality, monitor for adverse effects, and signs of dependence.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Do not combine with alcohol or other CNS depressants.
- Warn about daytime drowsiness and impaired coordination.
- Do not abruptly stop medication; consult provider for tapering plan.
Special Considerations
Black Box Warnings:
- Potential for serious respiratory depression and dependence.
- Use with caution in elderly due to increased sensitivity and risk of falls.
Genetic Factors: None specifically identified.
Lab Test Interference: May affect liver function tests or other hepatic enzymes.
Overdose Management
Signs/Symptoms: Profound sedation, respiratory depression, coma, pinpoint pupils.
Treatment: Supportive care including airway management, supporting ventilation, activated charcoal if recent ingestion, and gastric lavage as appropriate. No specific antidote; consider use of barbiturate-specific rescue medications if available.
Storage and Handling
Storage: Store in a tight, light-resistant container at room temperature.
Stability: Stable under recommended storage conditions.